Van Hulzen Asset Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.14M | Sell |
8,156
-24
| -0.3% | -$3.36K | 0.08% | 149 |
|
|
2025
Q4 | $1M | Sell |
8,180
-143
| -2% | -$17.4K | 0.07% | 158 |
|
|
2025
Q3 | $924K | Buy |
8,323
+4
| +0% | +$455 | 0.07% | 167 |
|
|
2025
Q2 | $922K | Sell |
8,319
-242
| -3% | -$25.8K | 0.08% | 162 |
|
|
2025
Q1 | $959K | Sell |
8,561
-3,370
| -28% | -$348K | 0.09% | 152 |
|
|
2024
Q4 | $1.1M | Sell |
11,931
-201
| -2% | -$18.1K | 0.08% | 155 |
|
|
2024
Q3 | $1.02M | Buy |
12,132
+13
| +0.1% | +$992 | 0.07% | 160 |
|
|
2024
Q2 | $831K | Sell |
12,119
-2,336
| -16% | -$156K | 0.06% | 168 |
|
|
2024
Q1 | $1.06M | Buy |
14,455
+458
| +3% | +$35.2K | 0.07% | 163 |
|
|
2023
Q4 | $1.13M | Buy |
13,997
+300
| +2% | +$23.3K | 0.08% | 147 |
|
|
2023
Q3 | $1.03M | Buy |
13,697
+5,705
| +71% | +$439K | 0.08% | 147 |
|
|
2023
Q2 | $616K | Buy |
7,992
+921
| +13% | +$73.5K | 0.05% | 162 |
|
|
2023
Q1 | $587K | Buy |
7,071
+807
| +13% | +$66.8K | 0.06% | 161 |
|
|
2022
Q4 | $538K | Sell |
6,264
-1,410
| -18% | -$112K | 0.06% | 166 |
|
|
2022
Q3 | $473K | Buy |
7,674
+334
| +5% | +$21.1K | 0.06% | 172 |
|
|
2022
Q2 | $454K | Buy |
7,340
+814
| +12% | +$50.4K | 0.05% | 175 |
|
|
2022
Q1 | $388K | Sell |
6,526
-168,720
| -96% | -$10.8M | 0.04% | 201 |
|
|
2021
Q4 | $12.8M | Buy |
175,246
+58,281
| +50% | +$4.01M | 1.39% | 20 |
|
|
2021
Q3 | $8.17M | Buy |
116,965
+1,192
| +1% | +$83.7K | 1.22% | 28 |
|
|
2021
Q2 | $7.97M | Buy |
115,773
+3,502
| +3% | +$234K | 1.2% | 30 |
|
|
2021
Q1 | $7.26M | Sell |
112,271
-1,251
| -1% | -$80.7K | 1.16% | 32 |
|
|
2020
Q4 | $6.61M | Sell |
113,522
-12,512
| -10% | -$755K | 1% | 32 |
|
|
2020
Q3 | $7.96M | Sell |
126,034
-9,202
| -7% | -$638K | 1.2% | 29 |
|
|
2020
Q2 | $10.4M | Buy |
135,236
+6,128
| +5% | +$470K | 1.56% | 17 |
|
|
2020
Q1 | $9.65M | Buy |
129,108
+44,862
| +53% | +$3.1M | 2.08% | 12 |
|
|
2019
Q4 | $5.47M | Buy |
84,246
+73,013
| +650% | +$4.75M | 1.06% | 34 |
|
|
2019
Q3 | $712K | Sell |
11,233
-676
| -6% | -$44.2K | 0.15% | 101 |
|
|
2019
Q2 | $805K | Buy |
11,909
+3,617
| +44% | +$238K | 0.18% | 93 |
|
|
2019
Q1 | $539K | Buy |
8,292
+4,150
| +100% | +$276K | 0.15% | 105 |
|
|
2018
Q4 | $259K | Sell |
4,142
-4,418
| -52% | -$309K | 0.08% | 187 |
|
|
2018
Q3 | $661K | Buy |
+8,560
| New | +$646K | 0.18% | 100 |
|
|
2018
Q2 | – | Sell |
-3,249
| Closed | -$245K | – | 205 |
|
|
2018
Q1 | $245K | Sell |
3,249
-11,378
| -78% | -$904K | 0.08% | 165 |
|
|
2017
Q4 | $1.05M | Buy |
14,627
+7,155
| +96% | +$543K | 0.32% | 71 |
|
|
2017
Q3 | $605K | Buy |
7,472
+2,531
| +51% | +$194K | 0.2% | 93 |
|
|
2017
Q2 | $350K | Sell |
4,941
-27,002
| -85% | -$1.8M | 0.14% | 94 |
|
|
2017
Q1 | $2.17M | Sell |
31,943
-10,253
| -24% | -$721K | 0.99% | 41 |
|
|
2016
Q4 | $3.02M | Buy |
42,196
+18,648
| +79% | +$1.39M | 1.4% | 25 |
|
|
2016
Q3 | $1.86M | Buy |
23,548
+22,348
| +1,862% | +$1.82M | 1.01% | 38 |
|
|
2016
Q2 | $100K | Buy |
1,200
+100
| +9% | +$8.88K | 0.06% | 139 |
|
|
2016
Q1 | $101K | Sell |
1,100
-401
| -27% | -$36.2K | 0.06% | 140 |
|
|
2015
Q4 | $152K | Sell |
1,501
-200
| -12% | -$20.8K | 0.09% | 110 |
|
|
2015
Q3 | $167K | Sell |
1,701
-701
| -29% | -$77.9K | 0.11% | 112 |
|
|
2015
Q2 | $281K | Buy |
+2,402
| New | +$262K | 0.15% | 119 |
|
Other funds holding GILD
VCM
VPM
Van Hulzen Asset Management's GILD Position: Q1 2026 in Review
Van Hulzen Asset Management reduced its Gilead Sciences (GILD) stake by 0.29% in Q1 2026, selling an estimated $3.36K and leaving 8,156 shares worth $1.14M. The position accounts for 0.08% of the portfolio, ranked #149.
Van Hulzen Asset Management first reported a position in GILD in Q2 2015 and has held it in 43 quarters since. The position peaked at $12.8M in Q4 2021. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Van Hulzen Asset Management held 8,156 shares of Gilead Sciences worth $1.14M as of Q1 2026.
- Van Hulzen Asset Management sold 24 Gilead Sciences shares in Q1 2026, an estimated $3.36K.
- Gilead Sciences made up 0.08% of Van Hulzen Asset Management's portfolio in Q1 2026, its #149 holding.
- Van Hulzen Asset Management first reported a position in Gilead Sciences in Q2 2015 and has held it in 43 quarters since.
- Van Hulzen Asset Management's Gilead Sciences position peaked at $12.8M in Q4 2021.
- 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Van Hulzen Asset Management's 13F filing for Q1 2026, filed 14 May 2026.